Get the Stockscreener App
9.60
1.13%
-0.11
After Hours:
9.75
0.15
+1.56%
Amneal Pharmaceuticals Inc stock is traded at $9.60, with a volume of 1.40M.
It is down -1.13% in the last 24 hours and up +3.56% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$9.71
Open:
$9.68
24h Volume:
1.40M
Relative Volume:
0.88
Market Cap:
$3.02B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-14.11
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-2.14%
1M Performance:
+3.56%
6M Performance:
+12.54%
1Y Performance:
+15.11%
1-Day Range:
$9.49
$9.69
1-Week Range:
$9.49
$10.16
52-Week Range:
$6.685
$10.34
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.60 | 3.05B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
141.13 | 62.79B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.65 | 47.25B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
8.72 | 39.56B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.36 | 22.11B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
425.42 | 19.84B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops - msn.com
FDA approves Amneal's bimatoprost 0.01% generic - Eyes On Eyecare
A Look at Amneal Pharmaceuticals's Valuation Following FDA Approval of Generic LUMIGAN - Yahoo Finance
Amneal Pharmaceuticals Positioned for Significant Growth with Strong Product Momentum and Strategic Advantages - TipRanks
FDA approves Amneal’s generic bimatoprost for glaucoma treatment - Investing.com
Amneal Pharmaceuticals receives FDA approval for bimatoprost ophthalmic solution - TipRanks
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - GlobeNewswire
$685M Market Opportunity: Amneal's Generic Glaucoma Treatment Gets FDA Green Light for Patient Care - Stock Titan
Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033, Report by DataM Intelligence - Yahoo Finance
AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) Receives $12.00 Average PT from Analysts - MarketBeat
Whats the fair value of Amneal Pharmaceuticals Inc stockJuly 2025 PreEarnings & Smart Money Movement Alerts - خودرو بانک
Goldman Sachs Group Inc. Sells 36,556 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Tech Rally: Does Amneal Pharmaceuticals Inc stock have upside surprise potentialQuarterly Profit Report & Short-Term High Return Ideas - خودرو بانک
Caxton Associates LLP Takes $339,000 Position in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
FDA Accepts New Drug Application for Parkinson’s Disease Treatment - Docwire News
Stop Loss: Is Amneal Pharmaceuticals Inc a potential multi baggerJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - خودرو بانک
AQR Capital Management LLC Boosts Stake in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Excessive Daytime Sleepiness Pipeline Insight 2025: Amneal’s FDA Approval of Sodium Oxybate Oral Solution, Novel Orexin Agonists, and Next-Generation Sleep-Wake Modulators Redefine Narcolepsy Care | D - Barchart.com
Amneal expects to meet or top annual guidance - MSN
Jones Financial Companies Lllp Takes $1.73 Million Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Excessive Daytime Sleepiness Pipeline Insight 2025: Amneal's - openPR.com
Woodline Partners LP Has $12.60 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Is Amneal Pharmaceuticals Inc in a long term uptrend2025 Year in Review & Stepwise Entry and Exit Trade Signals - خودرو بانک
Acadian Asset Management LLC Has $21.76 Million Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Aug Rallies: Can Amneal Pharmaceuticals Inc continue delivering strong returns2025 Momentum Check & Target Return Focused Picks - خودرو بانک
Analyst Downgrade: What are the future prospects of Amneal Pharmaceuticals Inc2025 Key Highlights & Weekly High Momentum Picks - خودرو بانک
Aug Big Picture: Does Amneal Pharmaceuticals Inc. have pricing powerGap Up & Weekly Top Performers Watchlists - خودرو بانک
Portfolio Update: Can Amneal Pharmaceuticals Inc continue delivering strong returnsEarnings Overview Summary & Risk Controlled Swing Alerts - خودرو بانک
Aug Final Week: Is Amneal Pharmaceuticals Inc stock undervalued right nowQuarterly Profit Summary & Daily Growth Stock Investment Tips - خودرو بانک
Nasdaq Moves: Is Amneal Pharmaceuticals Inc forming a double bottomQuarterly Trade Report & Long-Term Capital Growth Strategies - خودرو بانک
Amneal secures FDA approval for sodium oxybate solution - World Pharmaceutical Frontiers
Aug Outlook: Can Amneal Pharmaceuticals Inc continue delivering strong returnsWeekly Profit Recap & Consistent Profit Alerts - خودرو بانک
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 52-Week HighShould You Buy? - MarketBeat
Amneal receives FDA approval of treatment for narcoleptic sufferers - ROI-NJ
Ophthalmic Packaging Market Worth USD 23.65 Billion by 2034 | Towards Packaging - GlobeNewswire Inc.
Ieq Capital LLC Takes $288,000 Position in AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Why Amneal (AMRX) Stock Is Up Today - Yahoo Finance
Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem - Seeking Alpha
Amneal Pharmaceuticals Wins US FDA Approval for Generic Version of Narcolepsy Drug Xyrem - MarketScreener
Amneal receives US FDA approval of Sodium Oxybate Oral Solution - MarketScreener
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewswire
150,000 Narcolepsy Patients Get New Option: Amneal's FDA-Approved Generic Breaks Single-Maker Market - Stock Titan
Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing (AMRX) - Seeking Alpha
Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts - Nasdaq
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Raymond James Financial Inc. - MarketBeat
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
2.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):